Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (DE:1AEA)
FRANKFURT:1AEA
Holding DE:1AEA?
Track your performance easily
1AEA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€306.00 - €560.00
Previous Close€550
Volume0.00
Average Volume (3M)7.00
Market Cap
€33.38B
Enterprise Value€31.47B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Feb 27, 2025EPS Estimate
€1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding59,194,488
10 Day Avg. Volume0
30 Day Avg. Volume7
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)7.95
Price to Sales (P/S)86.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue147.64
Enterprise Value/Gross Profit28.39
Enterprise Value/Ebitda-69.01
Forecast
1Y Price Target
€612.54Price Target Upside11.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Argenx Se News
Bulls Say, Bears Say
Bulls Say
EarningsARGX reported yet another strong quarter of Vyvgart sales, beating consensus expectations for the 11th consecutive quarter.
Growth PotentialExperts are enthusiastic about the mechanism of action of efgartigimod for the treatment of myositis, highlighting safety and convenient dosing as key differentiators.
Market PositionAnalysts remain confident in ARGX’s strong commercial execution and clinical expansion plans, viewing it as a core immunology holding.
Bears Say
Clinical Trials And EfficacyNipocalimab's clinESSDAI and ESSDAI doesn't seem competitive vs what has been seen historically, and the treatment effect could get lower in Phase 3.
Market CompetitivenessARGX announced it won't advance efgart in POTS due to lack of clinically meaningful improvements.
Safety ConcernsSafety concerns include numerical albumin drops and LDL increases with 15 mg/kg Q2W nipocalimab, which have not been seen with Vyvgart.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
23.10% Mutual Funds
12.47% Other Institutional Investors
62.85% Public Companies and
Individual Investors
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was €306.00 and its highest was €560.00 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 27, 2025 which is in 105 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 31, 2024. The company reported €1.317 earnings per share for the quarter, beating the consensus estimate of €0.139 by €1.178.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is €1.2.
How many shares outstanding does Argenx Se have?
Argenx Se has 59,796,272 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of €1.317 in its last earnings report, beating expectations of €0.139. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 48M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€612.54 (11.37% Upside)
€612.54 (11.37% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.28%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Earnings Call
Q3 2024
0:00 / 0:00
---
1AEA Stock 12 Month Forecast
Average Price Target
€612.54
▲(11.37% Upside)
Technical Analysis
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
33/36 ratings generated profit
1 Year Average Return
+39.90%
assigned a buy rating 15 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +39.90% per trade.
---